Rectal Cancer Stage III Clinical Trial
Official title:
Using CNN Image Recognition to Predict Rectal Cancer Outcomes
Investigator retrospective collect cases during 2010-2021 diagnosed as rectal adenocarcinoma with high quality CT images. Local advanced rectal cancer cases were labeled as "disease". Nor were defined " normal". Using artificial intelligence CNN on jupyter notebook with open phyton code to train and develop models capable to recognizing local advanced rectal cancer. Modify the phyton code for better predict rate and help physician to quickly evaluate disease severity for fresh rectal cancer cases.
From 2010.10.1~2021.12.31, rectal cancer patients with cT3-4 lesion was included. Collect high quality CT images with DICOM files in tumor segment. cT1-2, low rectal lesions, non-CRC cases were not included. Non-contrast and artificial defect images were also excluded. CT images were labeled as" diseased " when CRM were threatened (<2mm). All images were labeled according to judgment of 2 specialist. The data were separated into 2 parts. One for AI model training and testing, another for external validation. The training testing dataset was achieved by deep learning neural network and evaluating model accuracy performance. Then the model was applied into external validation dataset for real-world testing, evaluating coherent rate between AI and the Dr. decision. Furthermore, to see the cancer survival outcomes according to AI model prediction results. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05495308 -
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
|
||
Recruiting |
NCT04598984 -
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
|
||
Active, not recruiting |
NCT04246684 -
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
|
Phase 3 | |
Not yet recruiting |
NCT05830890 -
Sentinel Lymph Node Biopsy in Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT04503694 -
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
|
Phase 2 | |
Completed |
NCT02363374 -
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03561142 -
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
|
Phase 2 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT05148767 -
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
|
Phase 4 | |
Recruiting |
NCT06254521 -
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
|
Phase 2 | |
Completed |
NCT01325649 -
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
|
N/A | |
Recruiting |
NCT04970498 -
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
|
||
Active, not recruiting |
NCT03840239 -
TNT to Increase the Clinical Complete Response Rate for Distal LARC
|
Phase 2 | |
Active, not recruiting |
NCT03391843 -
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
|
Phase 2 |